Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Proteasome inhibition in multiple myeloma: lessons for other cancers.

Saavedra-García P, Martini F, Auner HW.

Am J Physiol Cell Physiol. 2020 Mar 1;318(3):C451-C462. doi: 10.1152/ajpcell.00286.2019. Epub 2019 Dec 25.

PMID:
31875696
2.

Time from first symptom onset to the final diagnosis of multiple myeloma (MM) - possible risks and future solutions: retrospective and prospective 'Deutsche Studiengruppe MM' (DSMM) and 'European Myeloma Network' (EMN) analysis.

Graziani G, Herget GW, Ihorst G, Zeissig M, Chaidos A, Auner HW, Duyster J, Wäsch R, Engelhardt M.

Leuk Lymphoma. 2020 Apr;61(4):875-886. doi: 10.1080/10428194.2019.1695051. Epub 2019 Nov 28.

PMID:
31779510
3.

Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor.

Morris C, Chabannon C, Masszi T, Russell N, Nahi H, Kobbe G, Krejci M, Auner HW, Pohlreich D, Hayden P, Basak GW, Lenhoff S, Schaap N, van Biezen A, Knol C, Iacobelli S, Liu Q, Celanovic M, Garderet L, Kröger N.

Bone Marrow Transplant. 2020 Feb;55(2):356-366. doi: 10.1038/s41409-019-0676-0. Epub 2019 Sep 18.

4.

Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3.

Tornatore L, Capece D, D'Andrea D, Begalli F, Verzella D, Bennett J, Acton G, Campbell EA, Kelly J, Tarbit M, Adams N, Bannoo S, Leonardi A, Sandomenico A, Raimondo D, Ruvo M, Chambery A, Oblak M, Al-Obaidi MJ, Kaczmarski RS, Gabriel I, Oakervee HE, Kaiser MF, Wechalekar A, Benjamin R, Apperley JF, Auner HW, Franzoso G.

Toxicol Rep. 2019 Apr 19;6:369-379. doi: 10.1016/j.toxrep.2019.04.006. eCollection 2019.

5.

Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension.

Bringhen S, Milan A, D'Agostino M, Ferri C, Wäsch R, Gay F, Larocca A, Offidani M, Zweegman S, Terpos E, Goldschmidt H, Cavo M, Ludwig H, Driessen C, Auner HW, Caers J, Gramatzki M, Dimopoulos MA, Boccadoro M, Einsele H, Sonneveld P, Engelhardt M.

J Intern Med. 2019 Jul;286(1):63-74. doi: 10.1111/joim.12882. Epub 2019 Apr 8.

6.

The coordinated action of VCP/p97 and GCN2 regulates cancer cell metabolism and proteostasis during nutrient limitation.

Parzych K, Saavedra-García P, Valbuena GN, Al-Sadah HA, Robinson ME, Penfold L, Kuzeva DM, Ruiz-Tellez A, Loaiza S, Holzmann V, Caputo V, Johnson DC, Kaiser MF, Karadimitris A, Lam EW, Chevet E, Feldhahn N, Keun HC, Auner HW.

Oncogene. 2019 Apr;38(17):3216-3231. doi: 10.1038/s41388-018-0651-z. Epub 2019 Jan 9.

7.

Author Correction: Bi-directional cell-pericellular matrix interactions direct stem cell fate.

Ferreira SA, Motwani MS, Faull PA, Seymour AJ, Yu TTL, Enayati M, Taheem DK, Salzlechner C, Haghighi T, Kania EM, Oommen OP, Ahmed T, Loaiza S, Parzych K, Dazzi F, Varghese OP, Festy F, Grigoriadis AE, Auner HW, Snijders AP, Bozec L, Gentleman E.

Nat Commun. 2018 Dec 18;9(1):5419. doi: 10.1038/s41467-018-07843-1.

8.

Author Correction: Bi-directional cell-pericellular matrix interactions direct stem cell fate.

Ferreira SA, Motwani MS, Faull PA, Seymour AJ, Yu TTL, Enayati M, Taheem DK, Salzlechner C, Haghighi T, Kania EM, Oommen OP, Ahmed T, Loaiza S, Parzych K, Dazzi F, Varghese OP, Festy F, Grigoriadis AE, Auner HW, Snijders AP, Bozec L, Gentleman E.

Nat Commun. 2018 Nov 14;9(1):4851. doi: 10.1038/s41467-018-07398-1.

9.

The HDAC6 inhibitor C1A modulates autophagy substrates in diverse cancer cells and induces cell death.

Kaliszczak M, van Hechanova E, Li Y, Alsadah H, Parzych K, Auner HW, Aboagye EO.

Br J Cancer. 2018 Nov;119(10):1278-1287. doi: 10.1038/s41416-018-0232-5. Epub 2018 Oct 15.

10.

Bi-directional cell-pericellular matrix interactions direct stem cell fate.

Ferreira SA, Motwani MS, Faull PA, Seymour AJ, Yu TTL, Enayati M, Taheem DK, Salzlechner C, Haghighi T, Kania EM, Oommen OP, Ahmed T, Loaiza S, Parzych K, Dazzi F, Varghese OP, Festy F, Grigoriadis AE, Auner HW, Snijders AP, Bozec L, Gentleman E.

Nat Commun. 2018 Oct 3;9(1):4049. doi: 10.1038/s41467-018-06183-4. Erratum in: Nat Commun. 2018 Nov 14;9(1):4851. Nat Commun. 2018 Dec 18;9(1):5419.

11.

Clinical proof of concept for a safe and effective NF-κB-targeting strategy in multiple myeloma.

Tornatore L, Capece D, D'Andrea D, Begalli F, Verzella D, Bennett J, Acton G, Campbell EA, Kelly J, Tarbit M, Adams N, Bannoo S, Leonardi A, Sandomenico A, Raimondo D, Ruvo M, Chambery A, Oblak M, Al-Obaidi MJ, Kaczmarski RS, Gabriel I, Oakervee HE, Kaiser MF, Wechalekar A, Benjamin R, Apperley JF, Auner HW, Franzoso G.

Br J Haematol. 2019 May;185(3):588-592. doi: 10.1111/bjh.15569. Epub 2018 Sep 26. No abstract available.

12.

European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when.

Caers J, Garderet L, Kortüm KM, O'Dwyer ME, van de Donk NWCJ, Binder M, Dold SM, Gay F, Corre J, Beguin Y, Ludwig H, Larocca A, Driessen C, Dimopoulos MA, Boccadoro M, Gramatzki M, Zweegman S, Einsele H, Cavo M, Goldschmidt H, Sonneveld P, Delforge M, Auner HW, Terpos E, Engelhardt M.

Haematologica. 2018 Nov;103(11):1772-1784. doi: 10.3324/haematol.2018.189159. Epub 2018 Aug 31. Review.

13.

An engineered, quantifiable in vitro model for analysing the effect of proteostasis-targeting drugs on tissue physical properties.

Loaiza S, Ferreira SA, Chinn TM, Kirby A, Tsolaki E, Dondi C, Parzych K, Strange AP, Bozec L, Bertazzo S, Hedegaard MAB, Gentleman E, Auner HW.

Biomaterials. 2018 Nov;183:102-113. doi: 10.1016/j.biomaterials.2018.08.041. Epub 2018 Aug 21.

14.

Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA).

Bringhen S, Milan A, Ferri C, Wäsch R, Gay F, Larocca A, Salvini M, Terpos E, Goldschmidt H, Cavo M, Petrucci MT, Ludwig H, Auner HW, Caers J, Gramatzki M, Boccadoro M, Einsele H, Sonneveld P, Engelhardt M; European Hematology Association, the European Myeloma Network and the Italian Society of Arterial Hypertension.

Haematologica. 2018 Sep;103(9):1422-1432. doi: 10.3324/haematol.2018.191288. Epub 2018 Jul 26. Review.

15.

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN).

Larocca A, Dold SM, Zweegman S, Terpos E, Wäsch R, D'Agostino M, Scheubeck S, Goldschmidt H, Gay F, Cavo M, Ludwig H, Straka C, Bringhen S, Auner HW, Caers J, Gramatzki M, Offidani M, Dimopoulos MA, Einsele H, Boccadoro M, Sonneveld P, Engelhardt M.

Leukemia. 2018 Aug;32(8):1697-1712. doi: 10.1038/s41375-018-0142-9. Epub 2018 Apr 25. Review.

16.

More convenient proteasome inhibition for improved outcomes.

Auner HW, Yong KL.

Lancet Oncol. 2018 Jul;19(7):856-858. doi: 10.1016/S1470-2045(18)30411-X. Epub 2018 Jun 1. No abstract available.

17.

Neighboring cells override 3D hydrogel matrix cues to drive human MSC quiescence.

Ferreira SA, Faull PA, Seymour AJ, Yu TTL, Loaiza S, Auner HW, Snijders AP, Gentleman E.

Biomaterials. 2018 Sep;176:13-23. doi: 10.1016/j.biomaterials.2018.05.032. Epub 2018 May 22.

18.

Differential Regulation of Human Bone Marrow Mesenchymal Stromal Cell Chondrogenesis by Hypoxia Inducible Factor-1α Hydroxylase Inhibitors.

Taheem DK, Foyt DA, Loaiza S, Ferreira SA, Ilic D, Auner HW, Grigoriadis AE, Jell G, Gentleman E.

Stem Cells. 2018 Sep;36(9):1380-1392. doi: 10.1002/stem.2844. Epub 2018 Jun 8.

19.

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives.

Gay F, Engelhardt M, Terpos E, Wäsch R, Giaccone L, Auner HW, Caers J, Gramatzki M, van de Donk N, Oliva S, Zamagni E, Garderet L, Straka C, Hajek R, Ludwig H, Einsele H, Dimopoulos M, Boccadoro M, Kröger N, Cavo M, Goldschmidt H, Bruno B, Sonneveld P.

Haematologica. 2018 Feb;103(2):197-211. doi: 10.3324/haematol.2017.174573. Epub 2017 Dec 7. Review.

20.

Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party.

Auner HW, Iacobelli S, Sbianchi G, Knol-Bout C, Blaise D, Russell NH, Apperley JF, Pohlreich D, Browne PV, Kobbe G, Isaksson C, Lenhoff S, Scheid C, Touzeau C, Jantunen E, Anagnostopoulos A, Yakoub-Agha I, Tanase A, Schaap N, Wiktor-Jedrzejczak W, Krejci M, Schönland SO, Morris C, Garderet L, Kröger N.

Haematologica. 2018 Mar;103(3):514-521. doi: 10.3324/haematol.2017.181339. Epub 2017 Dec 7.

21.

Analysis of hematopoietic recovery after autologous transplantation as method of quality control for long-term progenitor cell cryopreservation.

Pavlů J, Auner HW, Szydlo RM, Sevillano B, Palani R, O'Boyle F, Chaidos A, Jakob C, Kanfer E, MacDonald D, Milojkovic D, Rahemtulla A, Bradshaw A, Olavarria E, Apperley JF, Pello OM.

Bone Marrow Transplant. 2017 Dec;52(12):1599-1601. doi: 10.1038/bmt.2017.113. Epub 2017 Jun 26.

22.

ER stress and cancer: The FOXO forkhead transcription factor link.

Alasiri G, Fan LY, Zona S, Goldsbrough IG, Ke HL, Auner HW, Lam EW.

Mol Cell Endocrinol. 2018 Feb 15;462(Pt B):67-81. doi: 10.1016/j.mce.2017.05.027. Epub 2017 May 29. Review.

23.

C-reactive protein prior to myeloablative allogeneic haematopoietic cell transplantation identifies patients at risk of early- and long-term mortality.

Patel A, Szydlo RM, Auner HW, Kanfer EJ, MacDonald DH, Milojkovic D, Altaf S, Innes A, Gabriel I, Rahemtulla A, Chaidos A, Karadimitris A, Olavarria E, Apperley JF, Pavlů J.

Br J Haematol. 2018 Mar;180(6):889-892. doi: 10.1111/bjh.14454. Epub 2016 Nov 29. No abstract available.

24.

Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting.

Garderet L, Cook G, Auner HW, Bruno B, Lokhorst H, Perez-Simon JA, Sahebi F, Scheid C, Morris C, van Biezen A, Sobh M, Michallet M, Gahrton G, Schönland S, Kröger N.

Leuk Lymphoma. 2017 Apr;58(4):797-808. doi: 10.1080/10428194.2016.1228926. Epub 2016 Sep 21.

25.

Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting).

Bruno B, Auner HW, Gahrton G, Garderet L, Festuccia M, Ladetto M, Lemoli RM, Massaia M, Morris C, Palumbo A, Schönland S, Boccadoro M, Kröger N.

Leuk Lymphoma. 2016;57(6):1256-68. doi: 10.3109/10428194.2015.1131278. Epub 2016 Jan 6. Review.

26.

Inadequate fine-tuning of protein synthesis and failure of amino acid homeostasis following inhibition of the ATPase VCP/p97.

Parzych K, Chinn TM, Chen Z, Loaiza S, Porsch F, Valbuena GN, Kleijnen MF, Karadimitris A, Gentleman E, Keun HC, Auner HW.

Cell Death Dis. 2015 Dec 31;6:e2031. doi: 10.1038/cddis.2015.373.

27.

Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure.

Pitcher DS, de Mattos-Shipley K, Tzortzis K, Auner HW, Karadimitris A, Kleijnen MF.

EBioMedicine. 2015 May 28;2(7):642-8. doi: 10.1016/j.ebiom.2015.05.016. eCollection 2015 Jul.

28.

Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma.

Auner HW, Garderet L, Kröger N.

Br J Haematol. 2015 Nov;171(4):453-62. doi: 10.1111/bjh.13608. Epub 2015 Jul 27. Review.

PMID:
26213240
29.

Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years.

Auner HW, Szydlo R, Hoek J, Goldschmidt H, Stoppa AM, Morgan GJ, Moreau P, Attal M, Marit G, Russell N, Brune M, Cook G, Sonneveld P, Schönland S, Garderet L, Kröger N.

Bone Marrow Transplant. 2015 Feb;50(2):209-15. doi: 10.1038/bmt.2014.255. Epub 2014 Nov 10.

PMID:
25387088
30.

Recent advances and future directions in targeting the secretory apparatus in multiple myeloma.

Auner HW, Cenci S.

Br J Haematol. 2015 Jan;168(1):14-25. doi: 10.1111/bjh.13172. Epub 2014 Oct 9. Review.

PMID:
25296649
31.

Cutaneous presentation of an aggressive plasmablastic neoplasm indiscriminate between lymphoma and myeloma.

Johnston AC, Naresh K, Barwick T, May P, Karadimitris A, Auner HW.

Ann Hematol. 2015 Apr;94(4):691-2. doi: 10.1007/s00277-014-2226-6. Epub 2014 Oct 5. No abstract available.

PMID:
25281025
32.

Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells.

Auner HW, Moody AM, Ward TH, Kraus M, Milan E, May P, Chaidos A, Driessen C, Cenci S, Dazzi F, Rahemtulla A, Apperley JF, Karadimitris A, Dillon N.

PLoS One. 2013 Sep 17;8(9):e74415. doi: 10.1371/journal.pone.0074415. eCollection 2013.

33.

Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation.

Auner HW, Szydlo R, van Biezen A, Iacobelli S, Gahrton G, Milpied N, Volin L, Janssen J, Nguyen Quoc S, Michallet M, Schoemans H, El Cheikh J, Petersen E, Guilhot F, Schönland S, Ahlberg L, Morris C, Garderet L, de Witte T, Kröger N; Plasma Cell Dyscrasia Sub-committee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

Bone Marrow Transplant. 2013 Nov;48(11):1395-400. doi: 10.1038/bmt.2013.73. Epub 2013 May 27.

PMID:
23708704
34.

Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation.

Auner HW, Szydlo R, Rone A, Chaidos A, Giles C, Kanfer E, Macdonald DH, Marin D, Milojkovic D, Pavlu J, Apperley JF, Rahemtulla A.

Leuk Lymphoma. 2013 Oct;54(10):2200-4. doi: 10.3109/10428194.2013.773998. Epub 2013 Mar 4.

PMID:
23387937
35.

Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).

Weissinger F, Auner HW, Bertz H, Buchheidt D, Cornely OA, Egerer G, Heinz W, Karthaus M, Kiehl M, Krüger W, Penack O, Reuter S, Ruhnke M, Sandherr M, Salwender HJ, Ullmann AJ, Waldschmidt DT, Wolf HH.

Ann Hematol. 2012 Aug;91(8):1161-74. doi: 10.1007/s00277-012-1456-8. Epub 2012 May 26. Review.

PMID:
22638755
36.

Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare system.

Auner HW, Pavlu J, Szydlo R, Giles C, Kanfer E, Macdonald D, Marin D, Milojkovic D, Rezvani K, Goldman JM, Apperley JF, Landgren O, Rahemtulla A.

Br J Haematol. 2012 Apr;157(1):125-7. doi: 10.1111/j.1365-2141.2011.08906.x. Epub 2011 Nov 3. No abstract available.

37.

The life span of short-lived plasma cells is partly determined by a block on activation of apoptotic caspases acting in combination with endoplasmic reticulum stress.

Auner HW, Beham-Schmid C, Dillon N, Sabbattini P.

Blood. 2010 Nov 4;116(18):3445-55. doi: 10.1182/blood-2009-10-250423. Epub 2010 Jul 22.

PMID:
20651073
38.

LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: treatment outcome and risk factor analysis from a single centre.

Pavlů J, Auner HW, Ellis S, Szydlo RM, Giles C, Contento A, Rahemtulla A, Apperley JF, Naresh K, MacDonald DH, Kanfer EJ.

Hematol Oncol. 2011 Jun;29(2):75-80. doi: 10.1002/hon.956. Epub 2010 Jul 14.

PMID:
20635327
39.

High rate of stem cell mobilization failure after thalidomide and oral cyclophosphamide induction therapy for multiple myeloma.

Auner HW, Mazzarella L, Cook L, Szydlo R, Saltarelli F, Pavlu J, Bua M, Giles C, Apperley JF, Rahemtulla A.

Bone Marrow Transplant. 2011 Mar;46(3):364-7. doi: 10.1038/bmt.2010.141. Epub 2010 Jun 21.

PMID:
20562926
40.

Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase.

Pavlů J, Kew AK, Taylor-Roberts B, Auner HW, Marin D, Olavarria E, Kanfer EJ, MacDonald DH, Milojkovic D, Rahemtulla A, Rezvani K, Goldman JM, Apperley JF, Szydlo RM.

Blood. 2010 May 20;115(20):4018-20. doi: 10.1182/blood-2010-01-263624. Epub 2010 Mar 19.

42.

Oral and intestinal Candida colonization in patients undergoing hematopoietic stem-cell transplantation.

Zollner-Schwetz I, Auner HW, Paulitsch A, Buzina W, Staber PB, Ofner-Kopeinig P, Reisinger EC, Olschewski H, Krause R.

J Infect Dis. 2008 Jul 1;198(1):150-3. doi: 10.1086/588827.

PMID:
18491972
43.

A novel role for the Aurora B kinase in epigenetic marking of silent chromatin in differentiated postmitotic cells.

Sabbattini P, Canzonetta C, Sjoberg M, Nikic S, Georgiou A, Kemball-Cook G, Auner HW, Dillon N.

EMBO J. 2007 Nov 14;26(22):4657-69. Epub 2007 Oct 18.

44.

Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia.

Zebisch A, Staber PB, Delavar A, Bodner C, Hiden K, Fischereder K, Janakiraman M, Linkesch W, Auner HW, Emberger W, Windpassinger C, Schimek MG, Hoefler G, Troppmair J, Sill H.

Cancer Res. 2006 Apr 1;66(7):3401-8.

45.
46.
47.

Pulmonary infiltrates in patients with haematologic malignancies: transbronchial lung biopsy increases the diagnostic yield with respect to neoplastic infiltrates and toxic pneumonitis.

Mulabecirovic A, Gaulhofer P, Auner HW, Popper H, Krause R, Hesse C, Sill H.

Ann Hematol. 2004 Jul;83(7):420-2. Epub 2004 May 5.

PMID:
15133629
48.

High expression of the sister-chromatid separation regulator and proto-oncogene hSecurin occurs in a subset of myeloid leukaemias but is not implicated in the pathogenesis of aneuploidy.

Auner HW, Zebisch A, Schimek MG, Bodner C, Hiden K, Linkesch W, Haas OA, Beham-Schmid C, Sill H.

Leukemia. 2004 Feb;18(2):303-8.

PMID:
14671639
49.

Molecular typing of coagulase-negative staphylococcal blood and skin culture isolates to differentiate between bacteremia and contamination.

Krause R, Haberl R, Wölfler A, Daxböck F, Auner HW, Krejs GJ, Wenisch C, Reisinger EC.

Eur J Clin Microbiol Infect Dis. 2003 Dec;22(12):760-3. Epub 2003 Nov 7.

PMID:
14605936
50.

High-risk AML complicated by pulmonary aspergillosis: successful treatment with nonmyeloablative stem cell transplantation and long-term administration of voriconazole.

Eibl M, Auner HW, Zinke-Cerwenka W, Sill H, Dornbusch HJ, Linkesch W.

Ann Hematol. 2004 Feb;83(2):133-6. Epub 2003 Oct 3.

PMID:
14530879

Supplemental Content

Loading ...
Support Center